Anti-ALEM antibodies did not influence therapeutic effects or adverse reactions. Measurement of IL-21 might help to determine the risk of thyroid autoimmunity before starting ALEM to some ...

Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006 ...

A new study found that in about 10% cases of multiple sclerosis, the body begins producing a distinctive set of antibodies ...

New findings reveal how a specific immune response to the Epstein-Barr virus could trigger multiple sclerosis ... investigated the role of a distinct antibody signature against the Epstein ...

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, ...

Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

The projected revenue for the Multiple Sclerosis Drugs market in Niger is ... and interferons. Monoclonal antibodies are now being increasingly used. Additional information: Market values ...

Through research in the Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic is leading scientific advances in multiple sclerosis treatment.

The brain tissue sections were also stained with antibodies specific for oligodendrocytes ... offered neuroprotection in the murine multiple sclerosis model with experimental autoimmune ...

"Thus, progression is present in most, if not all, patients with multiple sclerosis, regardless of ... Moreover, high-efficacy monoclonal antibody therapy -- ocrelizumab (Ocrevus), rituximab ...